Product Images Tamsulosin Hydrochloride

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Tamsulosin Hydrochloride NDC 68071-2197 by Nucare Pharmaceuticals,inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

PDP - 68071 2197 03 A96

PDP - 68071 2197 03 A96

This is a medication product label for Tamsulosin HCI 0.4mg capsules. The label provides information on the manufacturer of the medication, its lot number, and expiration date. It also includes warnings, dosage instructions, and details on the packaging.*

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions (n=8) - tamsulosin fig1

This appears to be a figure or a graph with the title "Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-Dose Administration of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted and Fed Conditions". It shows the concentration of the drug in the blood over time (hours) after taking a single dose of the drug in both fasted and fed conditions. Without the visual aid, it is impossible to provide a more detailed description of the results.*

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

Figure 2A	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1 - tamsulosin fig2

This is a figure showing the mean change from baseline in total AUA Symptom Score in Study 1. The X-axis shows the duration of treatment in weeks and the Y-axis represents the mean change from baseline. There are two treatments being compared: treatment with -OO-0-08mg_~A= A -A04my_ O30 and treatment with placebo. There are different time points along with the study, represented on the X-axis, which range from 0 to 13 weeks. The total number of participants in the study is also shown for each time point.*

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 2B	Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2 - tamsulosin fig3

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1 - tamsulosin fig4

The text describes a figure showing the mean increase in peak urine flow rate in L/sec in Study 1. The figure indicates the treatment given, which includes various dosages of mg and a placebo. The study involved a total of 5 groups, with different sample sizes, and lasted for different durations in weeks.*

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2 - tamsulosin fig5

Chemical Structure - tamsulosin str

Chemical Structure - tamsulosin str

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.